Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback